HEPNET Position Statement-I, Case Definition, Classification, Screening & Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: A Resource for Primary and Secondary Care Physicians

  • Bushra Ali Fatima Memorial Hospital College of Medicine and Dentistry, Lahore
  • Lubna Kamani Liaquat National Hospital
  • Adnan Salim Shaikh Zayed Medical Complex Lahore
  • Altaf Alam Evercare Hospital Lahore
  • Bader Faiyaz Zuberi OMI Hospital Karachi
  • Javed Iqbal Farooqi Lifecare Hospital, Hayatabad Peshawar
  • Altaf Baqir Naqvi Medicare Hospital Multan
  • Zeeshan Ali Jinnah Sindh Medical University & Jinnah Postgraduate Medical Center Karachi
  • Shahid Majid The Indus Hospital and Health Network
  • Zahid Yasin Hashmi Liver center, Faisalabad
  • Asad A Choudhry Chaudhry Hospital, Gujranwala
  • Muhammad Salih
  • Anwaar Ahmed Khan Doctors Hospital and Medical Center
  • Syed M. Zahid Azam Director, National Institute of Liver & GI Diseases (NILGID)
  • Zaigham Abbas Zia ud din university hospital Karachi
  • Masood siddiq Rawalpindi Hospital
  • Arif Amir Nawaz Fatima Memorial Hospital, Lahore
Keywords: fatty liver disease, NAFLD, MASLD, MAFLD., Metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease

Abstract

The Hep-Net position paper comes at a significant time in the history of Metabolically Associated Fatty Liver Disease (MAFLD) due to the rapid rise in this disease entity in the past decade. Metabolically Associated Fatty Liver Disease, by its very name, encompasses several common metabolic disease entities, top among those being diabetes and obesity. For Pakistan, the situation is serious as it is among the top 10 countries globally regarding the prevalence of obesity and number one in terms of diabetes, with over a quarter of adults affected. There remains slight ambiguity as regards the nomenclature of MAFLD, with western societies preferring to remove the word “fatty” and substitute with `’steatotic” i.e. MASLD.

Regardless of names/titles the metabolic nature of the disease and its management remains the same and fortunately, that is something where universal consensus is present. Under the umbrella of Hep-Net, eminent hepatologists from all over Pakistan have pooled their efforts to formulate guidelines that are specifically tailored to the Pakistani population, its specific lifestyle and relevant interventions that are needed to treat fatty/steatotic liver disease. By virtue of its multi-systemic consequences, metabolic fatty liver disease represents the most significant and expensive disease entity, globally. Prevention, through public education and timely intervention in diagnosed cases will serve to avert a healthcare storm that will far outweigh viral hepatitis.

doi: https://doi.org/10.12669/pjms.41.3.10081

How to cite this: Ali B, Kamani L, Salim A, Alam A, Zuberi BF, Farooqi JI, et al. HEPNET Position Statement-I, Case Definition, Classification, Screening & Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: A Resource for Primary and Secondary Care Physicians. Pak J Med Sci. 2025;41(3):929-938. doi: https://doi.org/10.12669/pjms.41.3.10081

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2025-02-22
How to Cite
Ali, B., Kamani, L., Salim, A., Alam, A., Zuberi, B. F., Farooqi, J. I., Naqvi, A. B., Ali, Z., Majid, S., Hashmi, Z. Y., Choudhry, A. A., Salih, M., Khan, A. A., Syed M. Zahid Azam, Abbas, Z., siddiq, M., & Nawaz, A. A. (2025). HEPNET Position Statement-I, Case Definition, Classification, Screening & Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: A Resource for Primary and Secondary Care Physicians. Pakistan Journal of Medical Sciences, 41(3), 929-938. https://doi.org/10.12669/pjms.41.3.10081
Section
Guideline

Most read articles by the same author(s)